companiesCompany
InventisBio
aka 益方生物
InventisBio developed garsorasib, one of the two KRAS G12C pills approved in China in 2024, and the third-generation EGFR inhibitor befotertinib.
Overview
Garsorasib (D-1553) approved August 2024; befotertinib (D-0316) approved 2023 via Betta Pharmaceuticals for EGFR-mutant NSCLC; earlier programmes in gout and oestrogen receptor degraders.
Headquarters
Shanghai, CN
Scorecard
All companies#148of 680 companies, score 14
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +3
1 approved, 0 in phase 3, 0 earlier, 1 targets, 3 registry studies. Formula on the scorecards page.
Type
biotech · 688382.SS
Stage
Public
Website
Founded
2013
Pages like this
not linked directly; found by shared links- ProductIcotinib
Shares Betta Pharmaceuticals and the tag china.